In addition, NRF2 can be controlled by epigenetic modification, for instance, the hypermethylation of CPG sites in the KEAP1 promoter is frequent and leads to the downregulation of KEAP1 in several types of cancer [24,25,26,27]. Here, NFE2L2 is linked to cancer.